Goldman Sachs raised the firm’s price target on Humana (HUM) to $195 from $158 and keeps a Sell rating on the shares. Humana rose after a modest Q1 earnings beat driven by slightly better-than-expected medical and pharmacy cost trends in its Insurance segment, supported by favorable seasonality effects, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana price target raised to $270 from $220 at Truist
- Humana price target raised to $262 from $195 at UBS
- Humana price target raised to $269 from $252 at Guggenheim
- Humana Kept at Hold as Analyst Raises Price Target to $267 Amid Margin-Rebuild Focus and Uncertain Medical Cost Trends
- Humana price target raised to $180 from $176 at Barclays